Who to call at Kimia Therapeutics, and when
Fundz watches for the moments Kimia Therapeutics starts buying, and tells you who to reach.
- An alert the day Kimia Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kimia Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kimia Therapeutics. With Fundz connected, it knows.
Kimia Therapeutics and CStone Pharmaceuticals Collaborate on Clinical Development of KT-721 for Oncology Treatment.
Contract Type
agreement
BerkeleyBiotechnologyHealth CareTherapeuticsDescription
Kimia Therapeutics has announced a clinical collaboration agreement with CStone Pharmaceuticals to advance its lead oncology asset, KT-721, into Phase 1 clinical development. CStone will lead the study in mainland China and Australia while Kimia manages non-clinical activities and drug supply.
Quick answer
Kimia Therapeutics and CStone Pharmaceuticals Collaborate on Clinical Development of KT-721 for Oncology Treatment. (November 5, 2026). Kimia Therapeutics is based in Berkeley, California, United States.
- What agreement did Kimia Therapeutics announce on November 5, 2026?
- Kimia Therapeutics has announced a clinical collaboration agreement with CStone Pharmaceuticals to advance its lead oncology asset, KT-721, into Phase 1 clinical development. CStone will lead the study in mainland China and Australia while Kimia manages non-clinical activities and drug supply.
- What does Kimia Therapeutics do?
- Kimia Therapeutics is a biotechnology company that focuses on advancing small-molecule medicines in oncology and immunology.
- Where is Kimia Therapeutics based?
- Kimia Therapeutics is based in Berkeley, California, United States.
- Which similar companies announced agreements around the same time?
- Aarvik Therapeutics (November 3, 2026), Teva Pharmaceutical Industries Ltd (November 3, 2026), AbbVie Inc. (November 3, 2026) and Ocugen (November 10, 2026) also announced agreements within 45 days of Kimia Therapeutics.
Source: Fundz verified event record.
Other recent agreements in Therapeutics and Biotechnology
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Aarvik Therapeutics Enters Partnership with Laurus Labs for MUTTA™ ADC Development in India. (November 3, 2026)
- Teva and Samsung Bioepis Sign Agreement for U.S. Rights to Biosimilars Infliximab and Etanercept. (November 3, 2026)
- AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1. (November 3, 2026)
- Ocugen Enters Exclusive License Agreement with Celairis Therapeutics (November 10, 2026)
- BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease. (October 29, 2026)
- Wolves Foundation and Alexion extend partnership to support Wolves Disability FC and Wolves Wishes for three more years. (October 29, 2026)
Kimia Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.